الفهرس 
Acute lymphoblastic leukemiaOnly 14 pages are availabe for public view
 |  | from | 230 |  |  |
| | | from | 230 | | |
Abstract
Abstract
Background and Aim: Acute lymphoblastic leukemia (ALL) is regulated by various signaling molecules such as cytokines, chemokines and adhesion molecules in its microenvironment. A member of the CXC chemokine family called stromal cell-derived factor-1 (SDF-1 or CXCL12) interacts with CXC chemokine receptor 4. (CXCR4). It suggests that the CXCL12/CXCR4 axis contributes to the spread of hematological disorders and solid malignancies. So, the aim of the study was to assess the role of CXCL12 (stromal cell derived factor-1) in progression of acute lymphoblastic leukemia as part of malignant cell to niche intercommunication and micro-environmental role in tumor progression.
Subjects and methods: This study was a Case control study included 24 adult patients who were newly diagnosed as ALL before receiving any treatment, with another 20 age and sex matched healthy persons as a control. Two ml of bone marrow aspirate was collected from each patient and control group under complete aseptic conditions. Sample collected on sterile vacutainers; an EDTA vacutainer for centrifugation (at 1000 RPM) for approximately 20 minutes.
Results: the results of the current study revealed that, CXCL12 is highly expressed on acute lymphoblastic leukemia (ALL) cells. CXCL12 level is found to be very high in all patients’ range between 620 ng/l to 2475 ng/l with a median level of 900 with a (P > 0.001), on the other hand, the control group showed lower values ranging from 75 ng/l to 300 ng/l with a median level of 150. The correlation between CXCL12 d15 levels with minimal residual disease (MRD) levels on day 15 of treatment. We found that there was a statistically significant correlation between CXCl-12 level on D15 and MRD level on day 15 (P < 0.001).
Conclusion: this study was directed at accurately assessing the role of stromal derived factoroe-1 (SDF-1), which is the product of the gene CXCL12, in the progression of acute lymphoblastic leukemia and its role as a prognostic factor among Egyptian patients. This provided new insight and considerable scope into leukemic cell biology and may enable the development of novel therapeutic protocols aimed at preventing cancer cell proliferation and dissemination.